Good News for Convalescent Plasma?

A double-blind trial of 160 patients in Argentina offered promising results for convalescent plasma as a COVID-19 treatment, CIDRAP reports.
Fundacion INFANT researchers in Buenos Aires found that plasma from recovered patients with high antibody levels reduced the risk of severe illness by 48% compared to the placebo group, according to a New England Journal of Medicine article published yesterday.
Despite disappointing earlier trial results, the US FDA greenlit convalescent plasma for emergency use in hospitalized patients, The New York Times notes.
What makes this study different? It focused on older adults aged 65+, treated within 3 days of symptom onset, while earlier trials treated patients further along in their illness.

Comments +


Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top